Semaglutide vs Liraglutide: side-by-side comparison
Semaglutide and Liraglutide belong to the same class (GLP-1 receptor agonist). They share therapeutic approach but differ in mechanism nuances, half-life, side-effect profile and available formulations. This comparison summarises what is common and where they diverge.
| Property | Semaglutide | Liraglutide |
|---|---|---|
| Therapeutic class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| CAS | 910463-68-2 | 204656-20-2 |
| ATC | A10BJ06 | A10BJ02 |
| Molecular weight | 4113.6 g/mol | 3751.2 g/mol |
| Brands with this active ingredient | 2 | 1 |
What they share
Both are in the GLP-1 receptor agonist class, giving them a common pharmacological architecture and many shared safety and management points. Choice within the class comes down to mechanism nuances, half-life, side-effect profile and individual response.
Key differences
Differences within the GLP-1 receptor agonist class are what matter in practice: half-life, route of administration, equivalent doses, specific interactions, predominant side-effect profile and accumulated clinical experience. This page frames them; the prescribing information gives quantitative detail.
Mechanisms compared
Semaglutide: Semaglutide binds and activates the GLP-1 receptor, a G-protein coupled receptor expressed in pancreatic beta and alpha cells, the central nervous system and the gastrointestinal tract. Liraglutide: Liraglutide binds and activates the GLP-1 receptor in pancreatic beta and alpha cells, the central nervous system and the gastrointestinal tract.
Indications compared
Semaglutide: Semaglutide is approved in adults with type 2 diabetes, as monotherapy or in combination with other antidiabetic agents, to improve glycaemic control. Liraglutide: Liraglutide is approved in adults with type 2 diabetes mellitus, alone or in combination with other antidiabetic agents, to improve glycaemic control.
Safety profile
Semaglutide: The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation and abdominal discomfort, usually mild to moderate and tending to attenuate over weeks. Liraglutide: The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation and abdominal discomfort, generally mild to moderate and most pronounced during the initial dose escalation.
Frequently asked questions
Is Semaglutide better than Liraglutide? ▾
Neither is universally better. Semaglutide and Liraglutide share the GLP-1 receptor agonist class but differ in half-life, mechanism nuances and side-effect profile. The choice depends on the patient and the prescriber.
Can Semaglutide and Liraglutide be combined? ▾
Combining two ingredients from the same GLP-1 receptor agonist class is uncommon and, in most cases, adds no benefit over one at an appropriate dose. The decision is always the prescriber's.
Do they have the same side-effect profile? ▾
Partly yes — they share many GLP-1 receptor agonist class effects, with nuances by mechanism and dose. The prescribing information lists differences.
Products with Semaglutide
Products with Liraglutide
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.